Cargando…

Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury

BACKGROUND: The anti-inflammatory cytokine interleukin-10 (IL-10) has been explored previously as a treatment method for spinal cord injury (SCI) due to its ability to attenuate pro-inflammatory cytokines and reduce apoptosis. Primary limitations when using systemic injections of IL-10 are that it i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellenbrand, Daniel J., Reichl, Kaitlyn A., Travis, Benjamin J., Filipp, Mallory E., Khalil, Andrew S., Pulito, Domenic J., Gavigan, Ashley V., Maginot, Elizabeth R., Arnold, Mitchell T., Adler, Alexander G., Murphy, William L., Hanna, Amgad S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489327/
https://www.ncbi.nlm.nih.gov/pubmed/31039819
http://dx.doi.org/10.1186/s12974-019-1479-3
_version_ 1783414803023265792
author Hellenbrand, Daniel J.
Reichl, Kaitlyn A.
Travis, Benjamin J.
Filipp, Mallory E.
Khalil, Andrew S.
Pulito, Domenic J.
Gavigan, Ashley V.
Maginot, Elizabeth R.
Arnold, Mitchell T.
Adler, Alexander G.
Murphy, William L.
Hanna, Amgad S.
author_facet Hellenbrand, Daniel J.
Reichl, Kaitlyn A.
Travis, Benjamin J.
Filipp, Mallory E.
Khalil, Andrew S.
Pulito, Domenic J.
Gavigan, Ashley V.
Maginot, Elizabeth R.
Arnold, Mitchell T.
Adler, Alexander G.
Murphy, William L.
Hanna, Amgad S.
author_sort Hellenbrand, Daniel J.
collection PubMed
description BACKGROUND: The anti-inflammatory cytokine interleukin-10 (IL-10) has been explored previously as a treatment method for spinal cord injury (SCI) due to its ability to attenuate pro-inflammatory cytokines and reduce apoptosis. Primary limitations when using systemic injections of IL-10 are that it is rapidly cleared from the injury site and that it does not cross the blood–spinal cord barrier. OBJECTIVE: Here, mineral-coated microparticles (MCMs) were used to obtain a local sustained delivery of IL-10 directly into the injury site after SCI. METHODS: Female Sprague-Dawley rats were contused at T10 and treated with either an intraperitoneal injection of IL-10, an intramedullary injection of IL-10, or MCMs bound with IL-10 (MCMs+IL-10). After treatment, cytokine levels were measured in the spinal cord, functional testing and electrophysiology were performed, axon tracers were injected into the brainstem and motor cortex, macrophage levels were counted using flow cytometry and immunohistochemistry, and lesion size was measured. RESULTS: When treated with MCMs+IL-10, IL-10 was significantly elevated in the injury site and inflammatory cytokines were significantly suppressed, prompting significantly less cells expressing antigens characteristic of inflammatory macrophages and significantly more cells expressing antigens characteristic of earlier stage anti-inflammatory macrophages. Significantly more axons were preserved within the rubrospinal and reticulospinal tracts through the injury site when treated with MCMs+IL-10; however, there was no significant difference in corticospinal tract axons preserved, regardless of treatment group. The rats treated with MCMs+IL-10 were the only group with a significantly higher functional score compared to injured controls 28 days post-contusion. CONCLUSION: These data demonstrate that MCMs can effectively deliver biologically active IL-10 for an extended period of time altering macrophage phenotype and aiding in functional recovery after SCI.
format Online
Article
Text
id pubmed-6489327
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64893272019-06-04 Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury Hellenbrand, Daniel J. Reichl, Kaitlyn A. Travis, Benjamin J. Filipp, Mallory E. Khalil, Andrew S. Pulito, Domenic J. Gavigan, Ashley V. Maginot, Elizabeth R. Arnold, Mitchell T. Adler, Alexander G. Murphy, William L. Hanna, Amgad S. J Neuroinflammation Research BACKGROUND: The anti-inflammatory cytokine interleukin-10 (IL-10) has been explored previously as a treatment method for spinal cord injury (SCI) due to its ability to attenuate pro-inflammatory cytokines and reduce apoptosis. Primary limitations when using systemic injections of IL-10 are that it is rapidly cleared from the injury site and that it does not cross the blood–spinal cord barrier. OBJECTIVE: Here, mineral-coated microparticles (MCMs) were used to obtain a local sustained delivery of IL-10 directly into the injury site after SCI. METHODS: Female Sprague-Dawley rats were contused at T10 and treated with either an intraperitoneal injection of IL-10, an intramedullary injection of IL-10, or MCMs bound with IL-10 (MCMs+IL-10). After treatment, cytokine levels were measured in the spinal cord, functional testing and electrophysiology were performed, axon tracers were injected into the brainstem and motor cortex, macrophage levels were counted using flow cytometry and immunohistochemistry, and lesion size was measured. RESULTS: When treated with MCMs+IL-10, IL-10 was significantly elevated in the injury site and inflammatory cytokines were significantly suppressed, prompting significantly less cells expressing antigens characteristic of inflammatory macrophages and significantly more cells expressing antigens characteristic of earlier stage anti-inflammatory macrophages. Significantly more axons were preserved within the rubrospinal and reticulospinal tracts through the injury site when treated with MCMs+IL-10; however, there was no significant difference in corticospinal tract axons preserved, regardless of treatment group. The rats treated with MCMs+IL-10 were the only group with a significantly higher functional score compared to injured controls 28 days post-contusion. CONCLUSION: These data demonstrate that MCMs can effectively deliver biologically active IL-10 for an extended period of time altering macrophage phenotype and aiding in functional recovery after SCI. BioMed Central 2019-04-30 /pmc/articles/PMC6489327/ /pubmed/31039819 http://dx.doi.org/10.1186/s12974-019-1479-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hellenbrand, Daniel J.
Reichl, Kaitlyn A.
Travis, Benjamin J.
Filipp, Mallory E.
Khalil, Andrew S.
Pulito, Domenic J.
Gavigan, Ashley V.
Maginot, Elizabeth R.
Arnold, Mitchell T.
Adler, Alexander G.
Murphy, William L.
Hanna, Amgad S.
Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury
title Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury
title_full Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury
title_fullStr Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury
title_full_unstemmed Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury
title_short Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury
title_sort sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489327/
https://www.ncbi.nlm.nih.gov/pubmed/31039819
http://dx.doi.org/10.1186/s12974-019-1479-3
work_keys_str_mv AT hellenbranddanielj sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT reichlkaitlyna sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT travisbenjaminj sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT filippmallorye sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT khalilandrews sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT pulitodomenicj sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT gaviganashleyv sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT maginotelizabethr sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT arnoldmitchellt sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT adleralexanderg sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT murphywilliaml sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury
AT hannaamgads sustainedinterleukin10deliveryreducesinflammationandimprovesmotorfunctionafterspinalcordinjury